HLS THERAPEUTICS INC (HLS.CA) Stock Price, Forecast & Analysis
Canada • Toronto Stock Exchange • TSX:HLS • CA40390B1094
HLS.CA Key Statistics, Chart & Performance
The current stock price of HLS.CA is 4.5 CAD. In the past month the price decreased by -6.05%. In the past year, price increased by 7.14%.
HLS.CA Technical Analysis
HLS.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HLS.CA. HLS.CA may be in some trouble as it scores bad on both profitability and health.
HLS.CA Financial Highlights
Over the last trailing twelve months HLS.CA reported a non-GAAP Earnings per Share(EPS) of -0.62. The EPS increased by 34.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.07% | ||
| ROE | -22.87% | ||
| Debt/Equity | 0.8 |
HLS.CA Forecast & Estimates
8 analysts have analysed HLS.CA and the average price target is 8.35 CAD. This implies a price increase of 85.58% is expected in the next year compared to the current price of 4.5.
For the next year, analysts expect an EPS growth of 36.47% and a revenue growth -3.29% for HLS.CA
HLS.CA Ownership
HLS.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.37 | 2.907B | ||
| GSD | DEVONIAN HEALTH GROUP INC | N/A | 1.908B | ||
| CRON | CRONOS GROUP INC | 36.85 | 1.344B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.117B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.1 | 884.516M | ||
| GUD | KNIGHT THERAPEUTICS INC | 122.56 | 579.854M | ||
| WEED | CANOPY GROWTH CORP | N/A | 560.059M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 386.926M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 26.72 | 365.328M | ||
| TSND | TERRASCEND CORP | N/A | 313.013M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About HLS.CA
Company Profile
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Company Info
HLS THERAPEUTICS INC
10 Carlson Court, Suite 701
Etobicoke ONTARIO M9W 6L2 CA
CEO: Christopher Nutt
Employees: 92
Phone: 16474959000
HLS THERAPEUTICS INC / HLS.CA FAQ
Can you describe the business of HLS THERAPEUTICS INC?
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
What is the current price of HLS stock?
The current stock price of HLS.CA is 4.5 CAD.
Does HLS stock pay dividends?
HLS.CA does not pay a dividend.
What is the ChartMill rating of HLS THERAPEUTICS INC stock?
HLS.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in HLS THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HLS.CA.
What is HLS THERAPEUTICS INC worth?
HLS THERAPEUTICS INC (HLS.CA) has a market capitalization of 140.72M CAD. This makes HLS.CA a Micro Cap stock.